Peptides have become one of the fastest-growing topics in wellness, longevity, weight management, fitness, and performance medicine. Social media is filled with testimonials promising better recovery, improved body composition, more energy, increased libido, healthier skin and hair, and even anti-aging benefits. But there is an important distinction that consumers need to understand:
A peptide being sold online—or even being discussed widely in the wellness community—does not mean that it has been proven safe, effective, accurately dosed, or manufactured to pharmaceutical standards.
At Rezilir Health, we believe patients deserve access to emerging therapies only within a framework of appropriate medical evaluation, informed consent, laboratory monitoring, and individualized risk assessment.
What is the “grey market” for peptides?
The term “grey-market peptide” is commonly used to describe peptides purchased outside conventional FDA-approved medication channels. Consumers may encounter them through websites, social-media sellers, wellness communities, friends, or companies marketing products as “research use only.” The problem is that the label on the vial may tell you what the product is supposed to contain—but it does not necessarily tell you what is actually in the vial.
The product-quality problem
One of the biggest concerns with nontraditional peptide sources is product quality. Research examining falsified peptide medicines has demonstrated substantial variability in both the amount and purity of the active ingredient. In one systematic analysis of falsified polypeptide drugs available on the Belgian market, cysteine-containing peptides demonstrated purity ranging from approximately 5% to 75%. Some products contained little or none of the expected active ingredient.
Contamination is another concern
The same Belgian study identified lead and arsenic in some falsified peptide preparations. Some samples contained lead or arsenic concentrations reaching up to approximately ten times the ICH toxicity limit for parenteral drugs. The arsenic identified was predominantly in an inorganic form associated with greater toxicity concerns. Repeated exposure to contaminants is especially concerning when people are using these products chronically.
“My friend is taking it” is not a medical evaluation
Another growing trend is people obtaining peptides from friends, acquaintances, online communities, or websites and then determining their own dosing schedules. This creates a significant clinical problem. A peptide that may be tolerated by one person may not be appropriate for another person because of differences in age, medical history and medications.
The dosing problem
Another major issue is that many grey-market peptides do not have an established, FDA-approved dosing regimen for the purpose for which consumers are using them. Online protocols frequently involve doses, combinations, and schedules developed through social-media communities rather than through adequately powered randomized clinical trials. Anecdotal reports such as “this worked for me” are not equivalent to evidence demonstrating that a treatment is safe and effective across a broad patient population.
The FDA landscape is changing—but “under consideration” does not mean “FDA approved”
There has been significant movement in the FDA’s regulatory review of peptides used in compounding. In July 2026, the FDA Pharmacy Compounding Advisory Committee considered several peptide-related bulk drug substances, including: BPC-157, KPV, TB-500, MOTS-C, Semax, and Epitalon. These substances were considered in the context of potential inclusion on the 503A bulk drug substances list. Patients should be cautious about social-media claims that a peptide has been “FDA approved,” “FDA recommended,” or is “about to be approved” simply because it appears on an FDA advisory committee agenda.
The unfortunate truth
A vial purchased from a website may look identical to a professionally prepared medication while having very different standards for identity, potency, purity, sterility, storage, and quality control. And when patients are choosing doses based on an online forum or a friend’s experience, they may be making significant medical decisions without knowing their baseline risk.
At Rezilir Health, our approach is to evaluate the person first, discuss what the evidence does—and does not—show, and then determine whether a peptide-based therapy is appropriate.
References:
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026. Mendias CL, Awan TM.
The Emerging Landscape of Performance-Enhancing Peptides Modulating GH-IGF1 Axis: Bridging the Gap Between Clinical Evidence and Patient Self-Administration. Frontiers in Endocrinology. 2026. Dominikowski A, Rękoś Z, Olejarz M, et al.
Under FDA, Unapproved Peptides Likely to Become More Widely Available. JAMA. 2026. Rita Rubin, MANews
Impurity Profiling of the Most Frequently Encountered Falsified Polypeptide Drugs on the Belgian Market. Talanta. 2018. Janvier S, Cheyns K, Canfyn M, et al.
